Thermo Fisher Completes Acquisition of Data Intelligence Company CorEvitas
By LabMedica International staff writers Posted on 16 Aug 2023 |
Thermo Fisher Scientific Inc. (Waltham, MA; USA) has completed the acquisition of CorEvitas, LLC (Waltham, MA; USA), a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, for USD 912.5 million in cash. The announcement of this acquisition was initially made on July 6, 2023. Following the completion of the acquisition, CorEvitas will be incorporated into Thermo Fisher's Laboratory Products and Biopharma Services division.
Real-world evidence involves gathering and analyzing data on patient healthcare utilization and outcomes collected from regular clinical practice. This area has been experiencing rapid growth. Both pharmaceutical and biotech companies, along with regulatory authorities, are showing increased interest in monitoring the safety of approved treatments. They are also focusing on evaluating the effectiveness and value of these treatments after their approval.
CorEvitas offers regulatory-grade, real-world evidence solutions to pharmaceutical and biotech companies with objective data and clinical insights aimed at enhancing patient care and clinical outcomes. CorEvitas manages a total of 12 registries, including nine autoimmune and inflammatory syndicated registries. The company has created a multi-therapeutic data intelligence platform that can build and scale several clinical registries in specific therapeutic areas. This platform collects structured clinical data from over 400 research sites and tracks more than 100,000 patients over time.
“We are very excited to welcome our new CorEvitas colleagues to Thermo Fisher,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “CorEvitas expands our clinical research business with highly complementary real-world evidence solutions, which is an increasingly important area and will help to enhance decision-making as well as the time and cost of drug development. We are excited by the opportunity to further accelerate innovation and advance productivity for our pharma and biotech customers in their work to deliver new medicines and therapeutics to benefit patients.”
Related Links:
Thermo Fisher Scientific Inc.
CorEvitas
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance